In the BioHarmony Drug Report Database

"Preview" Icon

Pertuzumab

Perjeta (pertuzumab) is an antibody pharmaceutical. Pertuzumab was first approved as Perjeta on 2012-06-08. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-2.

 

Trade Name

 

Perjeta
 

Common Name

 

pertuzumab
 

ChEMBL ID

 

CHEMBL2007641
 

Indication

 

breast neoplasms
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target

Image (chem structure or protein)

Pertuzumab structure rendering